
Beyond Statins: Bempedoic Acid, Inclisiran & Lp(a)
Tuesday, December 1st 2026 - 3:30 PM (IST)
10 days to go
12 doctors attending
Tuesday, December 1st 2026 - 3:30 PM (IST)
About this session
Despite the widespread use of statins, many patients continue to have elevated LDL cholesterol and residual cardiovascular risk. Emerging lipid-lowering therapies are expanding the options available for managing dyslipidaemia and reducing cardiovascular risk.
This session will explore the evolving role of bempedoic acid and inclisiran in lipid management, alongside the clinical significance of lipoprotein(a) [Lp(a)] as an independent cardiovascular risk factor. It will discuss their mechanisms of action, clinical evidence, patient selection and practical considerations in clinical practice.
Join us for an expert-led discussion on the latest advances in lipid management and the future of cardiovascular risk reduction beyond statins.
Faculty
Other details
Registration
Free
Duration
60 min
Replay
Yes
Certificate
No
Language
English
Explore other sessions

